Roquefort Therapeutics plc
ROQ.L
London Stock Exchange0.95
GBp
-0.05
- -
Roquefort Therapeutics plc
ROQ.L
(London Stock Exchange)
Recent
price
0.95
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Roquefort Therapeutics plc (ROQ.L) is a United Kingdom-based biotechnology company focused on the preclinical and clinical development of novel oncology medicines targeting hard-to-treat cancers. The company's core products and services encompass Midkine (MDK) antibodies demonstrating in vivo efficacy and orphan drug indications; MDK RNA oligonucleotides featuring gene-editing mechanisms; MDK mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics showing significant in vivo efficacy against solid tumors; and MK cell therapies with direct and natural killer cell-mediated anti-cancer activity. Incorporated in 2020 and headquartered at 85 Great Portland Street, First Floor, London, W1W 7LT, England, Roquefort Therapeutics operates primarily in the United Kingdom with partnered academic centers globally and pursues acquisitions in the medical biotechnology sector. In September 2025, the company signed heads of terms for a transformational reverse takeover acquisition of Coiled Therapeutics, Inc., valued at £30 million, to gain 100% ownership of a clinical-stage asset including AO-252, a first-in-class TACC3-targeted drug currently in Phase I trials (NCT06136884) for advanced solid tumors exhibiting encouraging efficacy and safety; the deal includes a proposed name change to Coiled Therapeutics plc and strategic partnership with A2A Pharmaceuticals, which commits £6 million in funding over two years. In October 2025, Roquefort raised £300,000 comprising £200,000 in advance subscriptions from strategic investors including Chairman Stephen West and a £100,000 loan from A2A Pharmaceuticals to fund transaction costs. Prior to this, the company carved out its Lyramid Pty Ltd subsidiary to existing shareholders ahead of a Pleiades Pharma sale announced in August 2025, shifting focus from preclinical assets to advanced clinical-stage opportunities.
FTSE 100 Live: London stocks pare gains; US futures point to mixed start